Author

Moses Chitsamatanga

Observed name: Chitsamatanga, Moses

Observed institution: University of Zimbabwe

OpenAlex ID: A5020522608

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

2022 · Pauline Amuge, Abbas Lugemwa, et al. · The Lancet HIV · 34

PDF

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

2022 · Anna Turkova, Hylke Waalewijn, et al. · The Lancet HIV · 23

PDF

Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial

2023 · Tom G Jacobs, Vivian Mumbiro, et al. · Clinical Infectious Diseases · 12

PDF

Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

2023 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 12

PDF

Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV

2024 · Lufina Tsirizani, Shaghayegh Mohsenian Naghani, et al. · Journal of Antimicrobial Chemotherapy · 4

PDF

Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial

2026 · Julia A Bielicki, Michelle Clements, et al. · The Lancet · 3

Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

2026 · Anna Turkova, Anna Turkova, et al. · The Lancet Child & Adolescent Health · 3

Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change

2023 · Tom G. Jacobs, Vivian Mumbiro, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 3

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

2026 · Diana Anena, Elizabeth Chappell, et al. · Contemporary Clinical Trials · 2

Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial

2024 · Hylke Waalewijn, Roeland E Wasmann, et al. · Journal of the Pediatric Infectious Diseases Society · 2

PDF

First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

2023 · Chishala Chabala, Tom G Jacobs, et al. · Journal of the Pediatric Infectious Diseases Society · 2

PDF

Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trial

2026 · Tom G. Jacobs, Vivian Mumbiro, et al. · EClinicalMedicine · 1

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV

2025 · Lufina Tsirizani, Hylke Waalewijn, et al. · Antimicrobial Agents and Chemotherapy · 1

Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

2026 · Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, et al. · The Lancet

Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial

2026 · Anne E M Kamphuis, Anne E M Kamphuis, et al. · The Lancet HIV

Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment

2026 · Laize Sílvia dos Anjos Botas Beca, Vivian Mumbiro, et al. · Journal of Antimicrobial Chemotherapy

Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial

2026 · Cinta Moraleda, Alfredo Tagarro, et al. · The Lancet

Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial

2026 · Adeodata R Kekitiinwa, Angus Jennings, et al. · The Lancet HIV

Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to

2026 · Anena, Diana, Chappell, Elizabeth, et al. · White Rose Research Online (University of Leeds, The University of Sheffield, University of York)

PDF

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

2025 · Diana Anena, Elizabeth Chappell, et al. · SSRN Electronic Journal

OA-286 Plasma concentrations of first line antituberculosis drugs in infants with HIV and severe pneumonia: a pharmacokinetic sub-study of the empirical trial

2023 · Chishala Chabala, Tom Jacobs, et al.

PDF

Works count: 25

Citation count: 119

H-index: 5

I10-index: 5